Literature DB >> 20971723

Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.

Seonghee Park1, Ji Aee Kim, Ka Young Joo, Shinkyu Choi, Eun-Nam Choi, Jung-A Shin, Ki-Hwan Han, Sung-Chul Jung, Suk Hyo Suh.   

Abstract

AIMS: Excessive endothelial globotriaosylceramide (Gb3) accumulation is associated with endothelial dysfunction and impaired endothelium-dependent relaxation in Fabry disease. In endothelial cells, K(Ca)3.1 channels contribute to endothelium-dependent relaxation. However, the effect of Gb3 on K(Ca)3.1 channels and the underlying mechanisms of Gb3-induced dysfunction are unknown. Herein, we hypothesized that Gb3 accumulation induces K(Ca)3.1 channel dysfunction and aimed to clarify the underlying mechanisms. METHODS AND
RESULTS: The animal model of Fabry disease, α-galactosidase A (Gla) knockout mice, displayed age-dependent K(Ca)3.1 channel dysfunction. K(Ca)3.1 current and the channel expression were significantly reduced in mouse aortic endothelial cells (MAECs) of aged Gla knockout mice, whereas they were not changed in MAECs of wild-type and young Gla knockout mice. In addition, K(Ca)3.1 current and the channel expression were concentration-dependently reduced in Gb3-treated MAECs. In both Gb3-treated and aged Gla knockout MAECs, extracellular signal-regulated kinase (ERK) and activator protein-1 (AP-1) were down-regulated and repressor element-1 silencing transcription factor (REST) was up-regulated. Gb3 inhibited class III phosphoinositide 3-kinase and decreased intracellular levels of phosphatidylinositol 3-phosphate [PI(3)P]. In addition, endothelium-dependent relaxation was significantly attenuated in Gb3-treated mouse aortic rings.
CONCLUSION: Gb3 accumulation reduces K(Ca)3.1 channel expression by down-regulating ERK and AP-1 and up-regulating REST and the channel activity by decreasing intracellular levels of PI(3)P. Gb3 thereby evokes K(Ca)3.1 channel dysfunction, and the channel dysfunction in vascular endothelial cells may contribute to vasculopathy in Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971723     DOI: 10.1093/cvr/cvq333

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

1.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

2.  Hypercalcemia induces a proinflammatory phenotype in rat leukocytes and endothelial cells.

Authors:  Nikolina Režić-Mužinić; Vedrana Cikeš-Čulić; Joško Božić; Tina Tičinović-Kurir; Ilza Salamunić; Anita Markotić
Journal:  J Physiol Biochem       Date:  2012-08-09       Impact factor: 4.158

3.  Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

Authors:  Justin J Kang; Liming Shu; James L Park; James A Shayman; Peter F Bodary
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-14       Impact factor: 4.052

4.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

Review 5.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

Review 6.  Ion channels and pain in Fabry disease.

Authors:  Carina Weissmann; Adriana A Albanese; Natalia E Contreras; María N Gobetto; Libia C Salinas Castellanos; Osvaldo D Uchitel
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 7.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

8.  Contradictory Effects of Superoxide and Hydrogen Peroxide on KCa3.1 in Human Endothelial Cells.

Authors:  Shinkyu Choi; Hye-Young Na; Ji Aee Kim; Sung-Eun Cho; Suk Hyo Suh
Journal:  Korean J Physiol Pharmacol       Date:  2013-06-11       Impact factor: 2.016

9.  Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study.

Authors:  Nurcan Üçeyler; Ann-Kathrin Kahn; Daniela Kramer; Daniel Zeller; Jordi Casanova-Molla; Christoph Wanner; Frank Weidemann; Zaza Katsarava; Claudia Sommer
Journal:  BMC Neurol       Date:  2013-05-24       Impact factor: 2.474

10.  Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.

Authors:  Hideaki Sueoka; Mikio Aoki; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.